Clarke & Anor, Application for Judicial Review (Rev1) [2026] NICA 31 (11 June 2026)

Executive summary

The Court of Appeal in Northern Ireland heard appeals and a cross-appeal arising from judicial review proceedings brought by Robert Clarke and Paul Pollins over delays in prison healthcare assessments for Opiate Substitution Therapy (OST). The appeal was concerned with the judge’s findings on Convention rights and declarations, including awards of damages of £5,000 to Pollins and £2,000 to Clarke.

Key points

• Parties: applicants Robert Clarke and Paul Pollins; respondents included the South-Eastern Health and Social Care Trust, with the Department of Health as a notice party.
• Core issue: delay in assessing prisoners for OST within prison healthcare, compared with timelier assessment for community patients and for prisoners already on OST when admitted.
• The judge had found breaches of Pollins’ Articles 3 and 8 rights and unlawful discrimination under Article 14; Clarke’s claim was limited to Article 14 discrimination.
• The judgment records chronic underfunding, a £4 million annual shortfall, insufficient staffing, and waiting times of 1–2 years or more with waiting lists commonly exceeding 100 prisoners.
• Relevant legal reasoning: the judge treated Articles 3 and 8 as imposing clear duties on the state to provide necessary prisoner healthcare and adequate specialist assessment.
• Sanctions/export-control angle: none expressly; the case is about prison healthcare and Convention rights, not sanctions or export controls.

Why it matters

This case is relevant to sovereign risk and national-risk analysis because it shows how persistent underfunding and service delays in a state detention system can become Convention-rights litigation with damages exposure. It does not bear directly on sanctions or export controls, but it is material to compliance expectations for publicly funded healthcare services in custody settings.

Implications

For compliance and litigation strategy, the judgment underscores that prolonged failure to assess prisoners for clinically indicated treatment can generate judicial review risk, damages exposure, and discrimination claims under the ECHR framework. Public authorities and prison healthcare providers should expect close scrutiny of resource constraints, waiting-list practices, and parity with community healthcare when defending delay-based challenges.